Medtronic’s 0.41% Gain Amid Legal Setback and FDA Approval Ranks 143rd in $770M Volume

. 17, , ranking 143rd in market activity. The stock’s performance was influenced by a key legal development involving a patent dispute with Boston Scientific. A federal court ruled in favor of Boston Scientific, granting a preliminary injunction that temporarily restricts Medtronic’s distribution of certain cardiac rhythm management devices. Analysts noted the decision could delay Medtronic’s market entry for the affected products but emphasized the company’s broader pipeline and long-term growth prospects remain intact.

Separately, the U.S. Food and Drug Administration (FDA) cleared Medtronic’s next-generation spinal cord stimulation system, expanding its neuromodulation portfolio. , which has shown consistent demand amid rising chronic pain prevalence. However, investors remained cautious about near-term earnings visibility due to ongoing cost pressures in global supply chains and regulatory scrutiny in key markets.

To build an accurate back-test I need to nail down a few practical details first: Market universe – Do you want to screen every listed U.S. common stock, or a specific universe (e.g., S&P 1500, Russell 3000, NASDAQ only, etc.)? , then sell them all at tomorrow’s close (i.e., ? Practical items – Slippage / commissions: include, or ignore? These choices affect the data we pull and the back-testing engine parameters. Let me know your preferences and I’ll start the data-retrieval and back-test run.